Comparison of valganciclovir versus foscarnet for the treatment of cytomegalovirus viremia in adult acute leukemia patients after allogeneic hematopoietic cell transplantation
Cytomegalovirus (CMV) reactivation increases treatment-related mortality (TRM) after allogeneic hematopoietic cell transplantation (allo-HCT). We analyzed 141 adult acute leukemia (AL) patients suffered allo-HCT between 2017 and 2021, who developed CMV viremia post-HCT and treated with valganciclovir or foscarnet, to evaluate effectiveness and safety of both drugs. Viremia clearance rates (14 and 21 d post treatment) and toxicities were similar in two groups. However, valganciclovir was associated with a lower cumulative incidence of CMV recurrence within 180 days (16.7% vs. 35.7%, p=0.029) post CMV clearance. Finally, 2-year TRM was lower in valganciclovir group (9.7% ± 0.2% vs. 26.2% ± 0.3%, p = 0.026), result a superior 2-year overall survival (OS; 88.1% ± 5.2% vs. 64.4% ± 5.5%, p = 0.005) and leukemia-free survival (LFS; 82.0% ± 5.9% vs. 58.9% ± 5.6%, p = 0.009). Valganciclovir might decrease CMV viremia recurrence and led to better long-term outcome than foscarnet in adult AL patients developed CMV viremia post-HCT. Considering the inherent biases of retrospective study, well-designed trials are warranted to validate our conclusion.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Leukemia & lymphoma - (2024) vom: 12. März, Seite 1-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhu, Jinjin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute leukemia |
|---|
| Anmerkungen: |
Date Revised 13.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/10428194.2024.2321322 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369653858 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369653858 | ||
| 003 | DE-627 | ||
| 005 | 20240313235645.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240313s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10428194.2024.2321322 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1327.xml |
| 035 | |a (DE-627)NLM369653858 | ||
| 035 | |a (NLM)38475670 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhu, Jinjin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of valganciclovir versus foscarnet for the treatment of cytomegalovirus viremia in adult acute leukemia patients after allogeneic hematopoietic cell transplantation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Cytomegalovirus (CMV) reactivation increases treatment-related mortality (TRM) after allogeneic hematopoietic cell transplantation (allo-HCT). We analyzed 141 adult acute leukemia (AL) patients suffered allo-HCT between 2017 and 2021, who developed CMV viremia post-HCT and treated with valganciclovir or foscarnet, to evaluate effectiveness and safety of both drugs. Viremia clearance rates (14 and 21 d post treatment) and toxicities were similar in two groups. However, valganciclovir was associated with a lower cumulative incidence of CMV recurrence within 180 days (16.7% vs. 35.7%, p=0.029) post CMV clearance. Finally, 2-year TRM was lower in valganciclovir group (9.7% ± 0.2% vs. 26.2% ± 0.3%, p = 0.026), result a superior 2-year overall survival (OS; 88.1% ± 5.2% vs. 64.4% ± 5.5%, p = 0.005) and leukemia-free survival (LFS; 82.0% ± 5.9% vs. 58.9% ± 5.6%, p = 0.009). Valganciclovir might decrease CMV viremia recurrence and led to better long-term outcome than foscarnet in adult AL patients developed CMV viremia post-HCT. Considering the inherent biases of retrospective study, well-designed trials are warranted to validate our conclusion | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Valganciclovir | |
| 650 | 4 | |a acute leukemia | |
| 650 | 4 | |a allogeneic hematopoietic cell transplantation | |
| 650 | 4 | |a cytomegalovirus | |
| 650 | 4 | |a foscarnet | |
| 700 | 1 | |a Xu, Mimi |e verfasserin |4 aut | |
| 700 | 1 | |a Ru, Yuhua |e verfasserin |4 aut | |
| 700 | 1 | |a Gong, Huanle |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Yiyang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Ziling |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xiang |e verfasserin |4 aut | |
| 700 | 1 | |a Tu, Yuqing |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Aining |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Huiying |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Zhengming |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Xiaowen |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Yue |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Chengcheng |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Suning |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Xiao |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Tiemei |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Depei |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia & lymphoma |d 1989 |g (2024) vom: 12. März, Seite 1-9 |w (DE-627)NLM012624047 |x 1029-2403 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:12 |g month:03 |g pages:1-9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10428194.2024.2321322 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 12 |c 03 |h 1-9 | ||